GS
CRSP icon

GTS Securities’s CRISPR Therapeutics CRSP Stock Holding History

GTS Securities’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-16,000
Closed -$752K – 1871
2024
Q3 		$752K Sell
16,000
-31,000
-66% -$1.57M ﹤0.01% 2429
2024
Q2 		$2.54M Sell
47,000
-18,200
-28% -$1.05M 0.01% 1320
2024
Q1 		$4.44M Buy
65,200
+9,100
+16% +$651K 0.01% 948
2023
Q4 		$3.51M Buy
56,100
+7,600
+16% +$420K 0.01% 1244
2023
Q3 		$2.2M Buy
+48,500
New +$2.5M ﹤0.01% 1443

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GTS Securities's CRSP Position: Q2 2026 in Review

GTS Securities sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 7,787 shares — an estimated $370K sold.

GTS Securities first reported a position in CRSP in Q2 2023 and held it in 8 quarters. The position peaked at $4.34M in Q4 2023. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • GTS Securities reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GTS Securities sold 7,787 CRISPR Therapeutics shares in Q2 2026, an estimated $370K.
  • GTS Securities first reported a position in CRISPR Therapeutics in Q2 2023 and held it in 8 quarters.
  • GTS Securities's CRISPR Therapeutics position peaked at $4.34M in Q4 2023.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.